Toll Free 1-877-266-8388 Tel: 1-408-747-0771
Fax: 1-408-470-7719
Quick Lead Time | Global Overnight Delivery Available
Purchase Order: info@signosisinc.com
HISPEC
Nuclear Receptor Reporter Stable Cell Lines
Nuclear receptors are a group of transcription factors that share a similar DNA-binding consensus sequence, making it difficult to differentiate between individual members using this sequence alone. To overcome this challenge, Signosis has developed the HISPEC Nuclear Receptor Stable Cell Lines. These cell lines are highly specific, utilizing the GAL4 system in combination with the ligand-binding domains of specific nuclear receptors to enable the precise analysis of individual receptor activation. The HiSPEC cell lines are designed to analyze the activation of specific nuclear receptors, including PPARα, PPARγ, PPARδ, GR (Glucocorticoid Receptor), AR (Androgen Receptor), and PXR (Pregnane X Receptor).
Principle
Traditional DNA regulatory element-luciferase reporter cell lines are commonly used to study endogenous or exogenous receptors and analyze receptor signaling pathways in a biological context. However, these reporter cell lines often lack specificity and uniqueness due to the similarity in binding sequences across the nuclear hormone receptor (NHR) family.
To overcome these limitations, Signosis has developed the HISPEC ligand-binding domain (LBD)-driven GAL4 reporter stable cell lines. This system employs a dual-vector approach: One vector contains eight copies of GAL4 upstream activator sequences (UAS) placed upstream of a luciferase reporter gene.; The other vector encodes a GAL4 DNA Binding Domain (DBD) fused to the LBD of a specific NHR of interest.
When a corresponding ligand is introduced, it activates the DBD-LBD fusion protein, enabling it to bind to the GAL4 UAS promoter. This interaction drives the expression of the luciferase reporter gene, producing a measurable signal. This innovative design minimizes cross-reactivity with other nuclear receptors, ensuring high sensitivity and specificity. Additionally, the chimeric receptors exhibit low toxicity in cells, even when overexpressed.
Stable clones were selected using dual antibiotic resistance markers (hygromycin and G418). Functional assays were then conducted, and clones demonstrating the highest induction folds were chosen, ensuring reliable and robust performance. These cell lines are ideal for screening drug compounds as potential agonists or antagonists.
Benefits
Highly Specific
The responsiveness of this stable cell line is driven by the specific ligand-binding domain with low/no cross-reactivity with other members of the nuclear receptor.
Mycoplasma Free
All cell lines have been tested negative for mycoplasma.
Low Toxicity
The chimeric receptors display less toxic effects on the cells.
We offer a highly sensitive Firefly Luciferase Substrate, which can accurately measure firefly luciferase activity in cells.
Highly Sensitive
More than 30-fold induction in response to the corresponding stimuli.
HiSPEC Nuclear Receptor Cell Lines
Product | SKU | Price (USD$) |
|---|---|---|
SL-3001-HS | $7,277.00 | |
SL-3002-HS | $7,277.00 | |
SL-3003-HS | $7,277.00 | |
SL-3004-HS | $7,277.00 | |
SL-3005 | $7,277.00 |
GAL4-UAS-Luc Cell Lines
Signosis has developed the GAL4-UAS-Luc Reporter Stable Cell Lines as a reliable, rapid, and sensitive method for analyzing the expression of your target gene of interest upon exposure to related ligands or other stimuli. These cell lines are transfected only with the GAL4-UAS-LUC vector, and are ready to be transfected with your customized GAL4 vector containing your NR of interest.
Product | SKU | Price |
|---|---|---|
SL-3000 | $3,927.00 | |
SL-4000 | $3,927.00 | |
SL-5000 | $3,927.00 |
Research Application
-
Studying the effects of ligand binding on GAL4-mediated transcriptional activity
-
Identifying ligands that activate or inhibit the target receptors by monitoring GAL4-driven luciferase expression
-
Screening for potential therapeutic compounds that modulate the target receptors by measuring changes in luciferase activity
-
Investigating the mechanisms underlying the regulation of the target receptors by analyzing the GAL4-mediated transcriptional response to various stimuli
-
Comparing the activity and selectivity of different compounds on the target receptors by using the GAL4 reporter assay
-
Studying the interaction between the target receptors and other signaling pathways or co-regulators by analyzing the changes in GAL4-mediated transcriptional activity upon co-expression of different genes or treatments.
-
Studying the effects of ligand binding on PPAR-gamma-mediated transcriptional activity
-
Identifying compounds that activate or inhibit PPAR-gamma activity by monitoring GAL4-driven luciferase expression
-
Investigating the role of PPAR-gamma in adipogenesis and glucose homeostasis by analyzing the GAL4-mediated transcriptional response to various stimuli
-
Screening for potential therapeutic compounds that target PPAR-gamma for the treatment of diabetes and other metabolic disorders
-
Studying the interaction between PPAR-gamma and other signaling pathways or co-regulators by analyzing the changes in GAL4-mediated transcriptional activity upon co-expression of different genes or treatments.
-
Studying the effects of ligand binding on PPAR-alpha or PPAR-delta-mediated transcriptional activity
-
Identifying compounds that activate or inhibit PPAR-alpha or PPAR-delta activity by monitoring GAL4-driven luciferase expression
-
Investigating the roles of PPAR-alpha and PPAR-delta in lipid metabolism and energy homeostasis by analyzing the GAL4-mediated transcriptional response to various stimuli
-
Screening for potential therapeutic compounds that target PPAR-alpha or PPAR-delta for the treatment of metabolic disorders, including dyslipidemia and obesity
-
Studying the interaction between PPAR-alpha or PPAR-delta and other signaling pathways or co-regulators by analyzing the changes in GAL4-mediated transcriptional activity upon co-expression of different genes or treatments.
